BioCryst Pharmaceuticals Expands HAE Portfolio
BioCryst Pharmaceuticals Inc. plans to acquire Astria Therapeutics Inc., adding navenibart to its portfolio.
The transaction values Astria's equity at about $920 million and its business at roughly $700 million, expected to close in the first quarter of 2026.
Navenibart is an injectable monoclonal antibody inhibitor of plasma kallikrein for the treatment of hereditary angioedema (HAE), a genetic disorder causing sudden swelling.
BioCryst has commercialized Orladeyo (berotralstat), an oral plasma kallikrein inhibitor for HAE treatment, and is advancing a pipeline of therapies.
Navenibart is an injectable monoclonal antibody inhibitor of plasma kallikrein for the treatment of HAE.
Author's summary: BioCryst expands HAE portfolio with Astria acquisition.
More News
- RBA payments review - What it means for Cuscal, banks & fintechs
- Opinion: Can an AI bot help with our workplace empathy problem?
- Captain KL to lead Cook Islands
- Coffee transformed her life — and the lives of women from her village in Uganda
- Creating a City & Guilds fit for the fourth industrial revolution
- The John Bolton Indictment Is Different
- Best Esports Betting Sites in 2025 - Top Bookmakers, Tips & Offers
- Israeli airstrikes killed 1 and injured 7 in Lebanon despite ceasefire – Ya Libnan
- Suspect in Kada Scott disappearance seen peering into woman's window in viral TikTok: sources
- Mentone Town Council Adopts 2026 Budget